Cancer care advances have led to increased numbers of cancer survivors and to improved understanding of late effects of cancers and their therapies and survivorship issues. Long-term follow-up of cancer patients is crucial in preventing and managing many of the late effects of cancers and their therapies. However, the literature has highlighted the high rates of loss to follow–up (loss to FU) after cancer treatment, particularly in patients with hematologic malignancies. In this review, we performed a systematic search of published literature on issues pertaining to loss to FU in survivors of hematologic malignancies, highlighting the predictors of increased or decreased rates of loss to FU. We found that the literature on survivors of adulthood cancers is very limited, in contrast to articles discussing young adult survivors of childhood cancers. Predictors and barriers of loss to FU were found to be variable in different studies; however, they shared some common themes, including disease-related, logistic, financial and educational factors. Furthermore, we discuss the potential interventions to mitigate the loss to FU, along with discussing research priorities in this area.

癌症护理的进步导致癌症幸存者的数量增加，并提高了对癌症及其治疗方法和幸存者问题的最新认识。癌症患者的长期随访对于预防和管理癌症及其疗法的许多后期影响至关重要。但是，文献强调癌症治疗后随访损失率高（FU丢失），尤其是血液系统恶性肿瘤患者。在这篇综述中，我们对血液恶性肿瘤幸存者中与FU丢失有关的问题进行了公开文献的系统检索，强调了FU丢失率升高或降低的预测因子。我们发现，与讨论儿童期癌症的年轻成年幸存者的文章相比，关于成年癌的幸存者的文献非常有限。在不同的研究中，尿素丢失的预测因素和障碍是可变的。但是，他们有一些共同的主题，包括与疾病有关，后勤，财务和教育因素。此外，我们讨论了减轻FU损失的潜在干预措施，并讨论了该领域的研究重点。